期刊文献+

紫杉醇联合表柔比星及护理干预治疗进展期乳腺癌的疗效研究 被引量:1

Efficacy of paclitaxel combined with epirubicin and nursing intervention in the treatment of advanced breast cancer
下载PDF
导出
摘要 目的观察护理干预在采用紫杉醇+表柔比星化疗方案治疗的进展期乳腺癌患者临床疗效中的作用。方法选取2015年4月~2017年4月在湖州市第一人民医院采用紫杉醇+表柔比星化疗方案进行治疗的74例进展期乳腺癌患者随机分为观察组与对照组,每组37例。对照组采用常规护理方法,观察组在对照组护理的基础上接受护理干预,比较2组临床缓解率。结果观察组总缓解率为67.5%显著高于对照组43.2%(χ2=4.107,P<0.05)。结论配合实施护理干预能在一定程度上提高紫杉醇联合表柔比星化疗方案对进展期乳腺癌的治疗效果。 Objective To observe the effect of nursing intervention in clinical nursing care of patients with advanced breast cancer treated with paclitaxel plus epirubicin chemotherapy regimen.Methods74patients with advanced breast cancer who were treated with paclitaxel+epirubicin chemotherapy from April2015to April^2017were randomly divided into the observation group and the control group,37cases in each group.The control group received routine nursing care,the observation group received nursing intervention on the basis of the nursing care of the control group,and the clinical remission rate of the two groups was compared.Results The total remission rate in the observation group was67.5%,significantly higher than that of the control group43.2%(χ2=4.107,P<0.05).Conclusion Combined with the implementation of nursing intervention can improve the therapeutic effect of paclitaxel combined with epirubicin chemotherapy to advanced breast cancer to a certain extent.
作者 林爱芳 陈玲萍 LIN Ai-Fang;CHEN Ling-ping(Department of Thyroid and Breast Surgery, Huzhou First People’s Hospital, Huzhou 313000, China;Department of Obstetrics and Gynecology, Taizhou Enze Medical Center (Group) Enze Hospital, Taizhou 318000, China)
出处 《中国生化药物杂志》 CAS 2017年第11期243-244,共2页 Chinese Journal of Biochemical Pharmaceutics
关键词 紫杉醇 表柔比星 进展期乳腺癌 护理干预 paclitaxel epirubicin advanced breast cancer nursing intervention
  • 相关文献

参考文献7

二级参考文献62

  • 1杨庄青,邹天宁,刘德权,李梅,王茂华,李少林.表柔比星联合紫杉醇治疗三阴性乳腺癌的效果分析[J].中国生化药物杂志,2014,34(6):113-115. 被引量:27
  • 2孙燕 周际昌.临床肿瘤内科手册[M].北京:人民卫生出版社,1998.45.
  • 3Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer[J]. N Engl J Med,2010,363(20) :1938-1948.
  • 4Carey LA,Dees EC,Sawyer L, et al. The triple negative para-dox: primary tumor chemosensitivity of breast cancer subtypes[J]. Clin Cancer Res,2007,13(8) :2329-2334.
  • 5Iwata H, Sato N, Masuda N, et al. Docetaxel followed by flu-orouracil/epirubicin/cyclophosphamide as neoadjuvant chemo-therapy for patients with primary breast cancer[J]. Jpn J ClinOncol,2011,41(7) :867-875.
  • 6Warm M, Kates R, Grobe-Onnebrink E, et al. Impact of tumorbiology,particularly triple-negative status,on response to preop-erative sequential, dose-dense epirubicin, cyclophosphamide fol-lowed by docetaxel in breast cancer[J]. Anti cancer Res, 2010,30(10):4251-4259.
  • 7Torrisi R.Balduzzi A’Ghisini R, et al. Tailored preoperative treat-ment of locally advanced triple negative (hormone receptor negativeand Her-2 negative) breast cancer with epirubicin, cisplatin.and infu-sional fluorouracil followed by weekly paclitaxel [J]. Cancer Che-mother Pharmacol,2008,62(4) :667-672.
  • 8Eisenhauer EA, Therasse P, Bogaerts J, et al. New response e-valuation criteria in solid tumours: revised RECIST guideline(version 1. 1) [J]. Eur J Cancer,2009,45(2) :228-247.
  • 9Huober J,von Minckwitz G,Denkert C et al. Effect of neoadju-vant anthracycline taxane-based chemotherapy in different bio-logical breast cancer phenotypes : overall results from the Gepar-Trio study[J]. Breast Cancer Res Treat,2010,124(1) : 133-140.
  • 10Wu J, Li S’Jia W, et al. Response and prognosis of taxanes andanthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer[J]. J Cancer Res Clin Oncol, 2011, 137(10)=1505-1510.

共引文献135

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部